tipifarnib has been researched along with Recrudescence in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forman, SJ; Frankel, P; Karanes, C; Kirschbaum, MH; Newman, EM; O'Donnell, MR; Popplewell, L; Pulone, B; Rincon, A; Stein, AS; Synold, T; Tuscano, J; Wright, J; Zain, JM | 1 |
| Allmer, C; Ansell, SM; Colgan, JP; Ding, H; Gupta, M; Habermann, TM; Hohl, R; Inwards, DJ; Johnston, PB; Kaufmann, SH; Kurtin, PJ; Link, BK; Loegering, D; Markovic, SN; Maurer, MJ; Micallef, IN; Nowakowski, GS; Peterson, K; Porrata, LF; Schneider, P; Tang, H; Thompson, CA; Weiner, G; Witzig, TE | 1 |
| De Porre, PM; DeVore, RF; Heymach, JV; Jia, X; Johnson, BE; Johnson, DH; Khuri, FR; Richards, HM; Safran, H; Schlabach, LL; Yunus, F; Zhang, S | 1 |
| De Porre, P; Dossey, L; Fan, H; Feldman, EJ; Gojo, I; Gotlib, J; Greenberg, PL; Harousseau, JL; Karp, JE; Lancet, JE; Lee, G; Löwenberg, B; Morris, LE; Raponi, M; Stone, RM; Wang, Y; Wright, JJ | 1 |
| Ange, D; Belly, RT; Bol, K; Buddharaju, L; End, DW; Gojo, I; Highsmith, WE; Hohl, RJ; Horak, I; Karp, JE; Kaufmann, SH; Kottke, TJ; Lancet, JE; Liesveld, J; Rosenblatt, J; Rybak, ME; Thibault, A; Tidwell, ML; Wright, JJ | 1 |
5 trial(s) available for tipifarnib and Recrudescence
| Article | Year |
|---|---|
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Quinolones; Recurrence; Risk Factors | 2011 |
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lymphoma; Male; Middle Aged; Quinolones; Recurrence; Treatment Outcome; Young Adult | 2011 |
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carcinoma, Small Cell; Disease-Free Survival; Farnesyltranstransferase; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinolones; Recurrence; Signal Transduction; Treatment Outcome | 2004 |
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; DNA-Binding Proteins; Farnesyltranstransferase; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nuclear Proteins; Prognosis; Proportional Hazards Models; Quinolones; Recurrence; Reproducibility of Results; Survival Analysis | 2008 |
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Bone Marrow; Cohort Studies; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Farnesyltranstransferase; Female; Genes, ras; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Prenylation; Quinolones; Recurrence; Remission Induction; Treatment Outcome | 2001 |
1 other study(ies) available for tipifarnib and Recrudescence
| Article | Year |
|---|---|
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |